The effect of IGF-I bioactivity on functional outcome after acute ischemic stroke.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29493

Enrollment

Registered

2012-07-12

Start date

2012-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

We will assess all patients at baseline, discharge and at 3 months. At baseline, data on clinical features of the ischemic stroke, demographic data, vascular risk factors and history, and use of medic

Eligibility

Inclusion criteria

Inclusion criteria: Patients will be eligible for inclusion if they are 18 years or older, have a clinical diagnosis of acute ischemic stroke within 24 hours from symptom onset.

Exclusion criteria

Exclusion criteria: Patients on insulin therapy will be excluded.

Design outcomes

Primary

Measure	Time frame
Functional outcome after 3 months as assessed with the modified Rankin Scale.	—

Secondary

Measure	Time frame
1. Neurological improvement defined as baseline adjusted NIHSS score at discharge; 2. Infarction size assessed with CT.	—

Contacts

Public ContactSusanne Fonville

Dr Molewaterplein 50-60 Ee-2240

s.fonville@erasmusmc.nl+31 (0)10 7044206

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)